the ability of AT 1 R blockers to selectively block Ang-II at the AT 1 R, thereby producing more complete inhibition was considered advantageous (Figure, A) . Although ACE inhibitors increase bradykinin by suppressing its degradation thereby enhancing vasodilation, this benefit may be offset by a nearly 20% risk of troublesome cough and angioneurotic edema. 5 However, AT 1 R blockers may also result in enhanced vasodilation via unopposed AT 2 R activation and downstream AT 2 -mediated signaling. 5 Other evidence indicates that angiotensin receptor blockers can also release kinins and increase bradykinin levels in hypertensive patients, 7 which may augment benefits that are offset by the risk of cough and angioedema. Randomized clinical trials mounted to resolve well-known arguments for using AT 1 R blockers have shown benefits of both ACE inhibitors and AT 1 R blockers for controlling blood pressure in hypertension. [8] [9] [10] A downside of chronic ACEinhibitor therapy in heart failure patients is that Ang-II levels increase and symptoms worsen. 5 Importantly, aging is associated with RAS dysregulation and increased Ang-II and other RAS components, which in turn may contribute to increased cardiovascular remodeling and risk in elderly patients. 4, 5 In diabetic nephropathy, excessive RAAS activation results in progressive renal damage.
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Up until a decade ago, the collective evidence favored the concept of a regulatory arm of the RAS with an ACE/ Ang-II/AT 1 R axis that mediates vasoconstriction, whereas under AT 1 R blockade the AT 2 R mediates vasodilation (Figure,  A) . Evidence over the last decade unraveled existence of a counter-regulatory arm of the RAS via an Ang-(1-7)/ACE-2/ mas receptor axis that opposes vasoconstrictor, proliferative, profibrotic, and prothrombotic actions of Ang-II (Figure) . 12, 13 The Ang-(1-7)/Mas axis regulates several signaling pathways, such as phospho-inositide 3-kinase/AKT and extracellular signal-regulated kinase pathways and involves downstream effectors such as nitric oxide, forkhead box O1, and cyclooxygenase 2. In the counter-regulatory and vasodepressor arm, both ACE-inhibitors and AT 1 receptor blockers can increase angiotensin-(1-7). 5, 10 This axis is a potential therapeutic target in cardio-renal disease.
In summary, RAAS blockade with ACE inhibitors or AT 1 R blockers is standard recommended therapy for hypertension, heart failure, and nondiabetic/diabetic chronic renal disease, and aldosterone blockade is used in selected patients. 5, [9] [10] [11] Clinicians recognize that optimal therapy is critical for survival
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The Angiotensin II Counter-Regulatory AT 2 Receptor Pathway Jugdutt Angiotensin II Counter-Regulatory AT 2 Pathway 1381 with a favorable outcome, and combination therapies are often needed. Over the last 2 decades, several laboratories have been searching for specific molecular targets that may lead to the development of therapies and strategies to optimize therapy of hypertension, heart failure, and chronic renal disease, prevent adverse remodeling, and improve outcome. Many studies have been conducted in experimental animal models and humans. However, therapy to limit adverse remodeling in patients with these diseases, especially the elderly, remains suboptimal, and hearts continue to enlarge after hypertension and heart failure. Angiotensinogen, angiotensin II, angiotensin III, angiotensin IV, and angiotensin-(1-7) are the main biologically active peptides of RAS. VIF is a non-RAS peptide that acts via AT 2 R. 14 ACE indicates angiotensin-converting enzyme; ACE-I, ACE inhibitor; ACE2, angiotensin-converting enzyme 2; Ang, angiotensin; ARB, angiotensin receptor blocker; AT1R and AT2R, Ang-II type 1 and type 2 receptor respectively; cGMP, cyclic guanosine 3′ 5′ monophosphate; EDHF, endothelin-derived hyperpolarizing factor; eNOS, endothelial nitric oxide synthase; Mas R, Ang 1 to 7 receptor; MRA, mineralocorticoid receptor antagonist; PAI-1, plasminogen activator inhibitor-1; PGI 2 , prostacyclin; PKCε, protein kinase Cε; RAS, renin-angiotensin system; RAAS, renin-angiotensin-aldosterone system; t-PA, tissue plasminogen activator; and VIF, vasoconstriction inhibiting factor. In this issue of Circulation, Salem and colleagues 14 tested the provocative and bold hypothesis that a novel peptide acts as an endogenous cofactor in Ang-II-mediated vasoregulatory effects. The observation that plasma Ang-II concentrations were not increased in patients with heart failure and chronic kidney disease triggered the idea that unknown endogenous cofactors may be involved in the action of Ang-II. 14, 15 They present a large volume of compelling data suggesting that this peptide, a fragment of chromogranin-A that they named vasoconstriction inhibiting factor (VIF), modulates vasoconstrictive effects of Ang-II and exerts vasodilator effects mediated by AT 2 R, and may provide a potential counter-regulatory mechanism against hypertension.
14 This interesting non-RAS peptide acting through AT 2 R further underscores the complexity of the RAS/RAAS (Figure, B) and need for more research to establish its importance as a potential target for the prevention and therapy of cardiovascular disease. Marie Curie, winner of separate Nobel Prizes for Physics and Chemistry, is credited with saying "be more curious about ideas."
It is known that chromogranin-A is produced by chromaffin cells of the adrenal medulla and other tissues and is elevated in pheochromocytomas. It serves as precursor to several functional peptides, including vasostatin I, vasostatin II, pancreastatin, catestatin, and parastatin, which negatively modulate autocrine and paracrine functions. [16] [17] [18] Some of these peptides, such as vasostatin I and vasostatin II, inhibit vasoconstriction while concentrations of catestatin are reduced and those of chromogranin-A are increased in hypertensive patients. Here Salem et al 14 report at least 7 important findings. First, they nicely demonstrated that VIF released from the adrenal glands and derived from chromogranin-A modulates Ang-II-induced vasoconstriction by testing different VIF concentrations on Ang-II-induced vasoconstriction and calculating the EC50. Second, they probed mechanisms and showed that VIF impairs Ang-II-induced phosphorylation of p38MAPK but not extracellular signal-regulated kinase 1/2. Third, they present evidence suggesting that elevated plasma VIF may modulate the harmful effects of Ang-II in chronic renal disease and heart failure patients, especially since chromogranin-A is also elevated in these patients. Fourth, they showed that VIF reduced Ang-II-induced increase in blood pressure in vivo. Fifth, they confirmed absence of homology in amino acid sequences between VIF and the other main Ang peptides. Sixth, they confirmed that VIF but neither scrambled nor truncated peptides caused a significant effect on Ang-II-induced vasoconstriction. Seventh, they addressed the affinity of VIF for AT 2 R by showing that VIF inhibits Ang-II-induced vasoconstriction in a large physiologically relevant range, and maintains its effect in the presence of L-N G-Nitro arginine methyl ester (hence independent of nitric oxide), but its effect is abolished by the AT 2 R blocker PD 123 319. These findings unmasking the nitric oxide-independent effect of VIF on the AT2 receptors further underscore the importance of AT 2 R in the regulation of blood pressure.
The overall findings of Salem et al 14 underscore the complexity of vasoregulation as pointed out by the authors. Importantly, the findings suggest a potentially novel strategy for promoting counterregulatory vasodilation thereby limiting hypertension, adverse remodeling, and heart failure. Whether targeting the VIF/AT 2 R pathway might be a potential approach for preventing adverse remodeling and improving outcome in hypertension warrants study. Whether VIF levels are decreased with aging and explain the poorer outcome in older patients also deserves study. The authors deserve to be applauded for the idea that non-RAS-derived peptides may interact with ≥1 of the 3 major RAS receptors (AT 1 R, AT 2 R, and Mas) and produce significant physiological and pathophysiological effects. This possibility opens up a new area of research into other biologically active peptides. The authors have suggested testing for interactions of VIF with other angiotensin peptides (such as angiotensinogen, Ang-II, Ang-III, Ang-IV, and Ang- [1] [2] [3] [4] [5] [6] [7] ), angioprotectin, and alamandine.
14 However, the possibility that peptide interactions may not always be beneficial but rather might be harmful and contribute to disease progression should also be considered.
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